ISDA

Deposition Date 2018-12-01

Release Date 2019-01-23

Last Version Date 2024-01-24

Entry Detail

PDB ID:

6IBY

Keywords:

TRANSFERASE

Title:

Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 6

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.51 Å

R-Value Free:

0.23

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 65 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3
Gene (Uniprot):PFKFB3
Chain IDs:A
Chain Length:428
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q16875 Pfam ID:PF01591, PF00300 EC:2.7.1.105

Ligand Molecules

BME

F6P

FLC

HAT

PO4

POP

Primary Citation

Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical properties.

Boutard, N, Bialas, A, Sabiniarz, A, Guzik, P, Banaszak, K, Biela, A, Bien, M, Buda, A, Bugaj, B, Cieluch, E, Cierpich, A, Dudek, L, Eggenweiler, H.M, Fogt, J, Gaik, M, Gondela, A, Jakubiec, K, Jurzak, M, Kitlinska, A, Kowalczyk, P, Kujawa, M, Kwiecinska, K, Les, M, Lindemann, R, Maciuszek, M, Mikulski, M, Niedziejko, P, Obara, A, Pawlik, H, Rzymski, T, Sieprawska-Lupa, M, Sowinska, M, Szeremeta-Spisak, J, Stachowicz, A, Tomczyk, M.M, Wiklik, K, Wloszczak, L, Ziemianska, S, Zarebski, A, Brzozka, K, Nowak, M, Fabritius, C.H.Show

Bioorg. Med. Chem. Lett. 29 646 653 (2019)

PMID: 30626557 DOI: 10.1016/j.bmcl.2018.12.034

Abstact

In oncology, the "Warburg effect" describes the elevated production of energy by glycolysis in cancer cells. The ubiquitous and hypoxia-induced 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) plays a noteworthy role in the regulation of glycolysis by producing fructose-2,6-biphosphate (F-2,6-BP), a potent activator of the glycolysis rate-limiting phosphofructokinase PFK-1. Series of amides and sulfonamides derivatives based on a N-aryl 6-aminoquinoxaline scaffold were synthesized and tested for their inhibition of PFKFB3 in vitro in a biochemical assay as well as in HCT116 cells. The carboxamide series displayed satisfactory kinetic solubility and metabolic stability, and within this class, potent lead compounds with low nanomolar activity have been identified with a suitable profile for further in vivo evaluation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures